Peptide Library

A pentadecapeptide derived from a sequence in human gastric juice. Most existing data is preclinical (animal models), exploring tissue repair, gut barrier, and tendon healing.

Synthetic fragment related to thymosin beta-4. Investigated in animal studies for cellular migration and tissue remodeling.

Protein that binds and inhibits members of the TGF-β superfamily, most notably myostatin. Myostatin inhibition increases muscle mass in animals and in rare human genetic conditions (myostatin-deficient individuals). Heavy biohacking / bodybuilding interest. Limited human-trial data for any indication.

Insulin-like Growth Factor 1, Long R3 variant — an analog of human IGF-1 with extended half-life (~20-30 hours vs. ~12 minutes for native IGF-1). Used in research; widely (and controversially) discussed in performance-enhancement communities. NOT FDA-approved for human use; the only approved IGF-1 product is mecasermin (native sequence).

Splice variant of IGF-1 (specifically IGF-1Ec) produced locally in muscle in response to mechanical loading. Theorized to drive satellite-cell activation and muscle hypertrophy. Heavy bodybuilding-community interest. Limited human clinical-trial evidence. NOT FDA-approved.

Mitochondrial-derived peptide encoded in the 12S rRNA. Preclinical data on insulin sensitivity, exercise capacity, and metabolic health. No FDA approval. Human data limited to small studies.

Tripeptide derivative of α-MSH studied in animal models of intestinal and skin inflammation.

Human cathelicidin antimicrobial peptide. Endogenous component of innate immunity with broad-spectrum antimicrobial, immunomodulatory, and wound-healing activity. Researched as a topical and systemic therapeutic across multiple indications; no FDA-approved formulation yet.

Small-molecule NNMT inhibitor (NOT a peptide — it's a quinoline derivative). NNMT (nicotinamide N-methyltransferase) is upregulated in obese white adipose tissue. Preclinical studies show 5-Amino-1MQ reduces adipocyte size and improves metabolic markers in obese mice. No human RCTs. Sold as a research chemical.

Synthetic peptidomimetic derived from angiotensin IV. Strong preclinical evidence for synaptogenesis (promoting new synapse formation) — described in animal studies as orders of magnitude more potent than BDNF in some assays. Of intense biohacking interest. NO human clinical trial data published.